Absorption & Permeability Services

By assessing compound permeability in the early stages of drug discovery, you will be able to identify compounds which are more likely to pose challenges during preclinical and clinical development. Eurofins Discovery offers a comprehensive panel of in vitro permeability services to provide our clients with accurate predictions of in vivo oral absorption for your compounds.
 
The permeability of compounds across cell membranes, such as intestinal epithelium, is a critical characteristic that determines the rate and extent of human absorption and ultimately affects the bioavailability of a drug candidate. Compounds with poor permeability are more likely to have poor Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) properties.
 
For rapid assessment of membrane permeability, we provide both standard and custom bidirectional permeability assays in multiple cell lines, including human Caco-2 and MDCK cells. To test for compound interactions with drug transporters, as recommended by regulatory agencies (P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K and more), we offer both substrate assessment and inhibition services in Caco-2, MDCK, HEK293, CHO, membrane vesicles, and various transfected cells lines.
 
We offer all Eurofins Discovery absorption and permeability assays in both standard human and animal model systems. You can order them individually, combined, or as a selection of key services provided in our drug candidate assessment packages to provide cost savings.